Video
Dr. Edward S. Kim on his "Wish List" for the Future of Immunotherapy in NSCLC
Author(s):
Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses immunotherapy in non-small cell lung cancer (NSCLC).
The impact of immunotherapy in NSCLC is unprecedented, said Kim. There are now second-line immunotherapy options with two different single-agents. In the next year, he would like to see expanded indications, most notably in the frontline setting. There are multiple studies being done that are combining immunotherapies with chemotherapy and with biologic therapy.
He is hopeful that there will be multiple approved combinations in 2017 as well as an effective biomarker to determine which patients will most benefit from immunotherapies.
